2022
Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System
Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2022, 1-10. DOI: 10.1002/9781119000822.hfcm083.pub2.Peer-Reviewed Original ResearchPeptide receptor radiotherapyMultiple endocrine neoplasiaDiffuse neuroendocrine systemClinical featuresHepatic metastasesNeuroendocrine tumorsGastroenteropancreatic systemNeuroendocrine systemInformed clinical careUnique clinical syndromeOngoing clinical trialsAbsence of symptomsCancer registry dataUnexplained incidenceReceptor radiotherapyClinical presentationRandomized trialsTherapeutic optionsClinical syndromeMultiple myelomaSomatostatin analoguesSpecific therapyRecent trialsSurvival resultsClinical trials
2020
Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice
Xu EY, Vosburgh E, Wong C, Tang LH, Notterman DA. Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice. Oncotarget 2020, 11: 2718-2739. PMID: 32733644, PMCID: PMC7367653, DOI: 10.18632/oncotarget.27660.Peer-Reviewed Original ResearchTumor suppressor geneCooperative functionMolecular mechanismsTumor suppressor RB1Tumorigenic effectsCre-loxP systemGenetic analysisPTEN pathwaySuppressor geneGenesNeuroendocrine tumorigenesisGenetic alterationsDeletionPTENTrp53MeninHomozygous deletionExpressing cellsPathwayPRBSignificant roleMiceTumorigenesisPreclinical murine modelsMechanism
2019
Two well-differentiated pancreatic neuroendocrine tumor mouse models
Wong C, Tang LH, Davidson C, Vosburgh E, Chen W, Foran DJ, Notterman DA, Levine AJ, Xu EY. Two well-differentiated pancreatic neuroendocrine tumor mouse models. Cell Death & Differentiation 2019, 27: 269-283. PMID: 31160716, PMCID: PMC7206057, DOI: 10.1038/s41418-019-0355-0.Peer-Reviewed Original ResearchConceptsMultiple endocrine neoplasia type 1Neuroendocrine tumorsMouse modelShort latencyPI3K/Akt/mTORPancreatic neuroendocrine tumorsPituitary neuroendocrine tumorsTumor mouse modelAkt/mTORMTOR inhibitor rapamycinCre-loxP systemNeuroendocrine cancerProlonged survivalProlonged latencyMEN1 patientsMouse insulin 1 promoterSame miceMen1 lossTherapeutic opportunitiesType 1Genetic syndromesPTEN lossEarly onsetTumorsTumor developmentAlleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors
Kobayashi S, Contractor T, Vosburgh E, Du YN, Tang LH, Clausen R, Harris CR. Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors. Oncogenesis 2019, 8: 16. PMID: 30796198, PMCID: PMC6386750, DOI: 10.1038/s41389-019-0127-1.Peer-Reviewed Original ResearchPancreatic neuroendocrine tumorsNeuroendocrine tumorsRIP1-Tag2 transgenic miceBeta-cell transcription factorsRIP1-Tag2 miceC57BL/6 genetic backgroundCell linesExpression of Insm1Stem cell markersLiver metastasesNonfunctioning tumorsB6 miceLarge tumorsMetastatic tumorsSevere diseaseRT2 miceAnimal modelsInsulinomaTransgenic miceCell transcription factorsInsulin productionGenetic backgroundTumorsHuman insulinomasCell markers
2017
Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System
Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2017, 1-12. DOI: 10.1002/9781119000822.hfcm083.ChaptersDiffuse neuroendocrine systemClinical featuresNeuroendocrine tumorsGastroenteropancreatic systemProgression-free survival benefitNeuroendocrine systemMultiple endocrine neoplasia syndromeInformed clinical careUnique clinical syndromeFive-year survivalOngoing clinical trialsAbsence of symptomsCancer registry dataEndocrine neoplasia syndromeUnexplained incidenceSurvival benefitClinical presentationHepatic metastasesClinical syndromeMultiple myelomaSurvival resultsClinical trialsRegistry dataNeoplasia syndromeClinical care
2016
Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5
Contractor T, Kobayashi S, da Silva E, Clausen R, Chan C, Vosburgh E, Tang LH, Levine AJ, Harris CR. Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5. Oncotarget 2016, 7: 30585-30596. PMID: 27105526, PMCID: PMC5058703, DOI: 10.18632/oncotarget.8874.Peer-Reviewed Original ResearchConceptsComplement C5Liver metastasesAdvanced tumorsNeuroendocrine tumorsMouse modelSmall primary tumorsPancreatic neuroendocrine tumorsTypes of tumorsSmall molecule antagonistsIntratumoral levelsPrimary tumorMale miceComplement C5aMetastasisTumorsMolecule antagonistsMiceHigh frequencySexual dimorphismHuman diseasesMalesFirst reportCD88CD68PMX53
2014
High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately
Chen W, Wong C, Vosburgh E, Levine AJ, Foran DJ, Xu EY. High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately. Journal Of Visualized Experiments 2014, 51639. PMID: 25046278, PMCID: PMC4212916, DOI: 10.3791/51639.Peer-Reviewed Original ResearchConceptsGraphical user interfaceLarge-scale image analysisImage analysis applicationsUser-friendly software applicationFree image analysis softwareImage analysisActive contour algorithmHigh-throughput image analysisHigh-throughput computationTime-consuming processUser interfaceSoftware applicationsImage analysis softwareAnalysis applicationsNumber of applicationsUneven illuminationQuality control workflowContour algorithmAnalysis softwareQuality imagesNoisy backgroundSoftwareAnalysis processImagesEasy quality controlHigh-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately
Chen W, Wong C, Vosburgh E, Levine A, Foran D, Xu E. High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately. Journal Of Visualized Experiments 2014 DOI: 10.3791/51639-v.Peer-Reviewed Original Research
2012
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Wong C, Vosburgh E, Levine AJ, Cong L, Xu EY. Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy. Journal Of Visualized Experiments 2012, 4218. PMID: 22929519, PMCID: PMC3486771, DOI: 10.3791/4218.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsNET cell linesDrug treatmentCell linesMetastatic neuroendocrine tumorsMinority of patientsHuman neuroendocrine tumor cell linesNeuroendocrine Tumor TherapyNew therapeutic targetsBiology of NETsNeuroendocrine tumor cell linesSingle-drug effectsHuman NET cell linesLocalized diseaseNET patientsSurvival benefitSystemic therapyRare tumorDrug effectsImmunohistochemical techniquesTherapeutic targetAnimal modelsNET biologyTumor cell linesHuman malignanciesHuman Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Wong C, Vosburgh E, Levine A, Cong L, Xu E. Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy. Journal Of Visualized Experiments 2012 DOI: 10.3791/4218-v.Peer-Reviewed Original ResearchHeat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors.
Gloesenkamp C, Nitzsche B, Lim A, Normant E, Vosburgh E, Schrader M, Ocker M, Scherübl H, Höpfner M. Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. International Journal Of Oncology 2012, 40: 1659-67. PMID: 22246317, DOI: 10.3892/ijo.2012.1328.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsApoptosisBenzoquinonesCell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationChick EmbryoChorioallantoic MembraneDose-Response Relationship, DrugFlow CytometryGastrointestinal NeoplasmsGene Expression ProfilingGene Expression Regulation, NeoplasticHSP90 Heat-Shock ProteinsHumansLactams, MacrocyclicNeuroendocrine TumorsPhosphatidylinositol 3-KinaseProtein Kinase InhibitorsProto-Oncogene Proteins c-aktReceptor, IGF Type 1Signal TransductionTOR Serine-Threonine KinasesConceptsShock protein 90IGF-1 receptorIPI-504Protein 90GEP-NETsNeuroendocrine tumorsHsp90 inhibitor IPI-504Heat shock protein 90Antiproliferative effectsGEP-NET cellsDose-dependent growth inhibitionGEP-NET treatmentPI3K/AKT/mTOR pathwayGastrointestinal neuroendocrine tumorsGastroenteropancreatic neuroendocrine tumorsAKT/mTOR pathwayCancer gene expressionAdditive antiproliferative effectsCell cycle arrestInnovative therapeutic approachesTyrosine kinase inhibitionGrowth inhibitionMechanism of actionGene expressionHsp90 inhibition
2010
A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum
Walsh KM, Choi M, Oberg K, Kulke MH, Yao JC, Wu C, Jurkiewicz M, Hsu LI, Hooshmand SM, Hassan M, Janson ET, Cunningham JL, Vosburgh E, Sackler RS, Lifton RP, DeWan AT, Hoh J. A pilot genome-wide association study shows genomic variants enriched in the non-tumor cells of patients with well-differentiated neuroendocrine tumors of the ileum. Endocrine Related Cancer 2010, 18: 171-180. PMID: 21139019, PMCID: PMC3221459, DOI: 10.1677/erc-10-0248.Peer-Reviewed Original ResearchMeSH KeywordsCase-Control StudiesCell DifferentiationCellsDNA Copy Number VariationsFemaleGenetic VariationGenome-Wide Association StudyHumansIleal NeoplasmsMaleMeta-Analysis as TopicMicroarray AnalysisNeoplasm StagingNeuroendocrine TumorsPilot ProjectsPolymorphism, Single NucleotideReview Literature as TopicConceptsLoss of heterozygosityDana-Farber Cancer InstituteTumor cellsMD Anderson Cancer CenterCarcinoid tumor cellsUppsala University HospitalPopulation-based controlsAnderson Cancer CenterCopy number variantsBonferroni-corrected levelBlood-derived DNACarcinoid cancerReal-time quantitative PCRCancer CenterNeuroendocrine tumorsUniversity HospitalNon-tumor cellsSerious conditionIndependent cohortCancer InstituteKb heterozygous deletionSmall sample sizePilot genome-wide association studyGenetic polymorphismsSingle nucleotide polymorphisms
2008
P53 mutations in lymphomas: position matters
Levine AJ, Vosburgh E. P53 mutations in lymphomas: position matters. Blood 2008, 112: 2997-2998. PMID: 18840714, DOI: 10.1182/blood-2008-07-167718.Peer-Reviewed Original Research
2001
Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis
Akpek G, Lenz G, Lee S, Sanchorawala V, Wright D, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo R. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplantation 2001, 28: 1105-1109. PMID: 11803350, DOI: 10.1038/sj.bmt.1703298.Peer-Reviewed Original ResearchConceptsStem cell transplantationAutologous blood stem cell transplantationBlood stem cell transplantationAbsolute lymphocyteT cellsImmunoglobulin levelsCell transplantationAL amyloidosisProliferative responsePost-stem cell transplantationT cell proliferative responsesNumber of CD4Post-transplant immunosuppressionCellular immune functionSerum immunoglobulin levelsT-cell immunosuppressionCell proliferative responsesT cell proliferationB cell functionInitial study groupImmunologic recoveryLymphoid recoveryPCP pneumoniaCell immunosuppressionLymphocyte subsets
2000
Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A
Scharrer I, Brackmann H, Sultan Y, Abshire T, Gazengel C, Ragni M, Gorina E, Vosburgh E, Kellermann E. Efficacy of a sucrose‐formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A. Haemophilia 2000, 6: 614-618. PMID: 11122384, DOI: 10.1046/j.1365-2516.2000.00432.x.Peer-Reviewed Original ResearchSafety and efficacy of solvent/detergent‐treated antihaemophilic factor with an added 80 °C terminal dry heat treatment in patients with haemophilia A
Powell J, Bush M, Harrison J, Abildgaard C, Vosburgh E, Thompson A, Hurst D. Safety and efficacy of solvent/detergent‐treated antihaemophilic factor with an added 80 °C terminal dry heat treatment in patients with haemophilia A. Haemophilia 2000, 6: 140-149. PMID: 10792471, DOI: 10.1046/j.1365-2516.2000.00407.x.Peer-Reviewed Original ResearchConceptsHeat-treated preparationsPlasma-derived factor VIII concentrateCrossover pharmacokinetic studyFactor VIII inhibitorsHome treatment programHemophilia A patientsTerminal dry heat treatmentFactor VIII concentrateViral inactivation processesSolvent/detergent treatmentA patientsFactor VIII preparationsClinical parametersVIII inhibitorsHaemophilia treatmentPatientsHemophilia AVIII concentrateTreatment programRare reportsAntihaemophilic factorPharmacokinetic studyDevelopment of inhibitorsTreatmentNon-enveloped virusesSucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy
Abshire T, Brackmann H, Scharrer I, Hoots K, Gazengel C, Powell J, Gorina E, Kellermann E, Vosburgh E. Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy. Thrombosis And Haemostasis 2000, 83: 811-816. PMID: 10896230, DOI: 10.1055/s-0037-1613925.Peer-Reviewed Original ResearchConceptsRFVIII-FSHome therapyAdverse eventsPharmacokinetic profileHemophilia ADrug-related adverse eventsRecombinant factor VIII productsIntermittent chest painFactor replacement therapyTreatment of bleedsSevere haemophilia AFirst clinical trialFactor VIII productsExcellent hemostatic controlSignificant adverse effectsFull-length rFVIIIChest painReplacement therapyClinical trialsViral inactivation stepsHemostatic controlExposure daysPatientsFactor VIIITherapy
1999
Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis
COMENZO R, SANCHORAWALA V, FISHER C, AKPEK G, FARHAT M, CERDA S, BERK J, DEMBER L, FALK R, FINN K, SKINNER M, VOSBURGH E. Intermediate‐dose intravenous melphalan and blood stem cells mobilized with sequential GM+G‐CSF or G‐CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal Of Haematology 1999, 104: 553-559. PMID: 10086794, DOI: 10.1046/j.1365-2141.1999.01216.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAmyloidosisAntineoplastic Agents, AlkylatingDrug CombinationsFemaleGranulocyte Colony-Stimulating FactorGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansInfusions, IntravenousLeukapheresisMaleMelphalanMiddle AgedSurvival AnalysisConceptsBlood stem cellsMobilization regimensG-CSFIntermediate dose (15-30 mg/m2, day 1) intravenous melphalanDose-intensive melphalanPhase 11 trialGrade 4 toxicityComplete haematological responseCells/AL amyloidosis patientsTerms of CD34Stem cellsActive regimenMobilization patientsDose melphalanOrgan involvementIntravenous melphalanCardiac amyloidD mortalityMonths 57AL amyloidosisAmyloidosis patientsHaematological responsePatientsDay 5
1998
Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients
Comenzo R, Vosburgh E, Falk R, Sanchorawala V, Reisinger J, Dubrey S, Dember L, Berk J, Akpek G, LaValley M, O'Hara C, Arkin C, Wright D, Skinner M. Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood 1998, 91: 3662-3670. PMID: 9573002, DOI: 10.1182/blood.v91.10.3662.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmyloidosisAntineoplastic Agents, AlkylatingCohort StudiesCombined Modality TherapyErythrocyte TransfusionFemaleHematopoietic Stem Cell TransplantationHumansKidneyLife TablesLiverMaleMelphalanMiddle AgedMyocardiumNervous SystemParaproteinsPlatelet TransfusionPrognosisRecurrenceSeverity of Illness IndexSurvival AnalysisTransplantation ConditioningTreatment OutcomeConceptsClonal plasma cell disorderPlasma cell disordersAL amyloidosisCell disordersPerformance statusComplete responseOrgan involvementAutologous stem cell transplantationBlood stem cell supportSignificant negative prognostic factorOrgan systemsDose-intensive melphalanDose-intensive therapyMedian performance statusPredominant cardiac involvementPerformance status 1Year of diagnosisGranulocyte-colony stimulating factorNegative prognostic factorStem cell supportBiopsy-proven amyloidosisProgressive organ failureStem cell transplantationMajor organ systemsPrior therapyDose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients
Comenzo R, Vosburgh E, Falk R, Sanchorawala V, Reisinger J, Dubrey S, Dember L, Berk J, Akpek G, LaValley M, O'Hara C, Arkin C, Wright D, Skinner M. Dose-Intensive Melphalan With Blood Stem-Cell Support for the Treatment of AL (Amyloid Light-Chain) Amyloidosis: Survival and Responses in 25 Patients. Blood 1998, 91: 3662-3670. DOI: 10.1182/blood.v91.10.3662.3662_3662_3670.Peer-Reviewed Original ResearchClonal plasma cell disorderPlasma cell disordersAL amyloidosisCell disordersPerformance statusComplete responseOrgan involvementAutologous stem cell transplantationBlood stem cell supportSignificant negative prognostic factorOrgan systemsDose-intensive melphalanDose-intensive therapyMedian performance statusPredominant cardiac involvementPerformance status 1Year of diagnosisGranulocyte-colony stimulating factorNegative prognostic factorStem cell supportBiopsy-proven amyloidosisProgressive organ failureStem cell transplantationMajor organ systemsPrior therapy